StockData

Endonovo Therapeutics, Inc. (ENDV) stock

ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)

Close on Oct 19, 2026Market cap $135.08KP/E –Yield –

Endonovo Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Endonovo Therapeutics's free cash flow for the twelve months ending Dec 31, 2019 was -$2.54M. For fiscal 2019 it was -$2.54M.

Annual free cash flow

PeriodPeriod endValueChange
FY2019Dec 31, 2019-$2.54M–
FY2018Dec 31, 2018-$2.89M–
FY2015Dec 31, 2015-$1.02M–
FY2014Dec 31, 2014-$909.30K–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2019Dec 31, 2019-$308.38K–
Q3 FY2019Sep 30, 2019-$1.02M–
Q4 FY2018Dec 31, 2018-$716.10K–
Q3 FY2018Sep 30, 2018-$830.38K–
Q2 FY2018Jun 30, 2018-$741.61K–
Q1 FY2018Mar 31, 2018-$599.72K–

More Endonovo Therapeutics figures

See a number that looks wrong?